Advanced Life Sciences’ Cethromycin Faces Anti-Infectives Panel With Solid Data
Firm is first of several near-term NDAs for community acquired pneumonia to come before FDA this year amid changing regulatory standards for anti-infective development.
Firm is first of several near-term NDAs for community acquired pneumonia to come before FDA this year amid changing regulatory standards for anti-infective development.